Al Za'abi Mohammed, Al Salam Suhail, Al Suleimani Yousuf, Ashique Mohammed, Manoj Priyadarsini, Nemmar Abderrahim, Ali Badreldin H
Department of Pharmacology and Clinical Pharmacy, College of Medicine and Health Sciences, Sultan Qaboos University, Muscat, Oman.
Department of Pathology, College of Medicine and Health Sciences, UAE University, Al Ain, United Arab Emirates.
Naunyn Schmiedebergs Arch Pharmacol. 2021 Feb;394(2):249-259. doi: 10.1007/s00210-020-01976-1. Epub 2020 Sep 16.
Cisplatin (CP) is nephrotoxic, and this side effect is used as an animal model for acute kidney injury (AKI). Earlier research has been focused on CP-induced AKI, with relatively little attention being paid to its ability to progress to chronic kidney disease (CKD) on repeated administration. We aimed here to test the dose dependency of its nephrotoxic actions by comparing various physiological, biochemical, molecular, and histopathological indices using repeated increasing doses of CP in rats. Furthermore, we investigated whether these doses of CP would result in the development of CKD. Biochemical, molecular, and histopathological measurements were conducted in plasma, urine, and/or kidneys of rats treated with increasing doses of CP at 1.6, 3.2, and 4.8 mg kg weekly for four consecutive weeks. These doses induced significant and dose-dependent elevations in most of the measured renal indices. These included increased renal fibrosis, as suggested histopathologically and biochemically by the significant increase in transforming growth factor-β1, significant decrease in actin alpha 2, and variable actions of collagen I and IV. CP also dose-dependently increased nuclear factor (erythroid-derived 2)-like 2 and caspase-3. Multiple repeated doses of CP (1.6 to 4.8 mg kg) induced multiple episodes of AKI, leading to CKD after the 4th weekly dose and confirmed that this dosage regimen could be used as an experimental animal model of AKI progressing to CKD. These actions were driven by inflammation, oxidative, and nitrosative stress.
顺铂(CP)具有肾毒性,这种副作用被用作急性肾损伤(AKI)的动物模型。早期研究主要集中在CP诱导的AKI上,而对其反复给药后进展为慢性肾脏病(CKD)的能力关注相对较少。我们的目的是通过在大鼠中使用反复递增剂量的CP比较各种生理、生化、分子和组织病理学指标,来测试其肾毒性作用的剂量依赖性。此外,我们研究了这些CP剂量是否会导致CKD的发生。对连续四周每周以1.6、3.2和4.8mg/kg递增剂量的CP处理的大鼠的血浆、尿液和/或肾脏进行生化、分子和组织病理学测量。这些剂量导致大多数测量的肾脏指标显著且呈剂量依赖性升高。其中包括肾纤维化增加,这在组织病理学和生化方面表现为转化生长因子-β1显著增加、肌动蛋白α2显著减少以及I型和IV型胶原的不同变化。CP还呈剂量依赖性增加核因子(红系衍生2)样2和半胱天冬酶-3。多次重复剂量的CP(1.6至4.8mg/kg)诱导了多次AKI发作,在第4周给药后导致CKD,并证实这种给药方案可作为AKI进展为CKD的实验动物模型。这些作用是由炎症、氧化和亚硝化应激驱动的。